Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

4.9K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathy.

Blood advances·2026
Same author

Polyomavirus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Multicenter Retrospective Analysis.

Transplantation and cellular therapy·2026
Same author

The dynamic myeloid-enriched microenvironment of glioblastoma: a major challenge to immunotherapy efficacy.

Frontiers in immunology·2026
Same author

Combined effects of mesenchymal stromal cells and antibiotic therapy on Enterobacter ventilator-associated pneumonia in rabbits.

Respiratory research·2026
Same author

Securing raw materials, reagents, and consumable supplies in the academic bioproduction UNITC network: because the chain is only as strong as its weakest link.

Bone marrow transplantation·2025
Same author

Optimized GMP-grade Wharton's jelly's mesenchymal stromal cells manufacturing and administration protocol for Graft versus Host disease prevention.

Current research in translational medicine·2025
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Aug 9, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

702

Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input.

Valentine Wang1, Mélanie Gauthier1,2, Véronique Decot1,2

  • 1CNRS, Lorraine University, IMoPA, F-54000, Nancy, France.

Cancers
|February 25, 2023
PubMed
Summary
This summary is machine-generated.

The United States and China lead in Chimeric Antigen Receptor T cells (CAR-T) therapy clinical trials, while Europe lags due to insufficient academic-industry collaboration. Europe is implementing regulatory and funding changes to boost CAR-T trial development.

Keywords:
Chimeric Antigen Receptor T cellacademic centerclinical trialregulation

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K
Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
05:16

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

145

Related Experiment Videos

Last Updated: Aug 9, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

702
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.4K
Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
05:16

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

145

Area of Science:

  • Oncology
  • Immunotherapy
  • Cellular Therapy

Background:

  • Chimeric Antigen Receptor T cells (CAR-T) therapy represents a significant advancement in cancer treatment.
  • Global leadership in CAR-T clinical trials is currently dominated by the United States and China.
  • Europe shows a notable delay in initiating CAR-T clinical trials compared to these leading nations.

Purpose of the Study:

  • To provide a global overview of CAR-T cell production in clinical trials.
  • To investigate the reasons behind Europe's lag in CAR-T therapy development.
  • To analyze the role of academic centers in CAR-T research and development.

Main Methods:

  • Systematic review of CAR-T cell clinical trials registered on ClinicalTrials.gov.
  • Global analysis of 1087 trials identified as of January 25, 2023.
  • Specific analysis of 58 European trials, with a focus on academic sponsorship.

Main Results:

  • A total of 1087 CAR-T clinical trials were identified globally.
  • European trials (58) lag significantly behind global leaders, with only 34 sponsored by academic centers.
  • A critical gap in academic-industry collaboration was observed in European CAR-T trials.

Conclusions:

  • Effective CAR-T cell therapy development and marketing authorization necessitate strong academic-industry partnerships.
  • The lack of such collaborations is a key factor contributing to Europe's delay in CAR-T trials.
  • Europe is actively pursuing regulatory reforms and increased funding to accelerate clinical trials for advanced therapy medicinal products (ATMPs).